Co­di­ak lands on Wall Street in sec­ond shot at IPO, rais­es $83M

Co­di­ak Bio­sciences fi­nal­ly hit Wall Street on Tues­day in its sec­ond at­tempt to go pub­lic, but didn’t quite reach its $100 mil­lion goal.

The Cam­bridge, MA-based biotech raised $83 mil­lion by pric­ing 5.5 mil­lion shares at $15, the mid­point of a $14 to $16 range. When Co­di­ak $CDAK sub­mit­ted pa­per­work with the SEC in Sep­tem­ber, it ini­tial­ly pro­posed a $100 mil­lion raise — up from the $86.2 mil­lion raise it sought back in April 2019. Un­fa­vor­able mar­ket con­di­tions led Co­di­ak to back out of the first IPO last Ju­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.